Dianthus Therapeutics (NASDAQ:DNTH) Price Target Increased to $51.00 by Analysts at Raymond James

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective hoisted by equities researchers at Raymond James from $34.00 to $51.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Raymond James’ price target would suggest a potential upside of 112.32% from the stock’s current price.

A number of other analysts have also recently issued reports on DNTH. Jefferies Financial Group increased their price objective on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Wedbush increased their price objective on shares of Dianthus Therapeutics from $24.00 to $33.00 and gave the stock an “outperform” rating in a research note on Friday, March 22nd. Finally, Stifel Nicolaus assumed coverage on shares of Dianthus Therapeutics in a research note on Thursday, February 15th. They issued a “buy” rating and a $44.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $42.40.

Dianthus Therapeutics Stock Up 2.9 %

DNTH traded up $0.68 during trading on Thursday, hitting $24.02. The company’s stock had a trading volume of 47,290 shares, compared to its average volume of 142,249. Dianthus Therapeutics has a one year low of $6.58 and a one year high of $33.77. The business’s 50 day simple moving average is $25.82 and its 200-day simple moving average is $17.11.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.40. The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.73 million. As a group, equities analysts forecast that Dianthus Therapeutics will post -1.92 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Dianthus Therapeutics by 21.1% during the fourth quarter. Vanguard Group Inc. now owns 153,646 shares of the company’s stock valued at $1,598,000 after acquiring an additional 26,769 shares in the last quarter. Octagon Capital Advisors LP grew its stake in shares of Dianthus Therapeutics by 15.4% in the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock worth $5,762,000 after buying an additional 74,000 shares in the last quarter. Vestal Point Capital LP purchased a new position in shares of Dianthus Therapeutics in the 4th quarter worth $1,404,000. Northern Trust Corp bought a new stake in shares of Dianthus Therapeutics in the 4th quarter worth about $159,000. Finally, Tower Research Capital LLC TRC bought a new stake in shares of Dianthus Therapeutics in the 4th quarter worth about $25,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.